JOSÉ
HERNÁNDEZ QUERO
Chercheur depuis 2023
Hospital Vall d'Hebron
Barcelona, EspañaPublications en collaboration avec des chercheurs de Hospital Vall d'Hebron (19)
2023
-
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
Frontiers in Cellular and Infection Microbiology, Vol. 13
2022
-
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
HIV Medicine, Vol. 23, Núm. 7, pp. 705-716
2021
-
Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 73, Núm. 7, pp. e2026-e2033
-
HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients
Journal of Biomedical Science, Vol. 28, Núm. 1
2020
-
Effects of Eradication of HCV on Cardiovascular Risk and Preclinical Atherosclerosis in HIV/HCV-Coinfected Patients
Journal of acquired immune deficiency syndromes (1999), Vol. 83, Núm. 3, pp. 292-300
2019
-
Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
Scientific Reports, Vol. 9, Núm. 1
2018
-
Dysregulation of the immune system in HIV/HCV-coinfected patients according to liver stiffness status
Cells, Vol. 7, Núm. 11
-
Human immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant
Open Forum Infectious Diseases, Vol. 5, Núm. 1
-
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: Results of the neurocognitive substudy of the SALT randomized clinical trial
Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 9, pp. 2444-2451
2017
-
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
The Lancet HIV, Vol. 4, Núm. 12, pp. e536-e546
-
Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study
HIV Medicine, Vol. 18, Núm. 7, pp. 482-489
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2016
-
Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics
Open Forum Infectious Diseases, Vol. 3, Núm. 2
2015
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
2011
-
New trends in infective endocarditis
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 29, Núm. SUPPL. 4, pp. 22-35
2008
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092
2007
-
Recomendaciones españolas sobre el uso adecuado de enfuvirtida
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 25, Núm. 2, pp. 131-142
-
Update on osteo-articular infections and severe skin and soft tissue infections
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 25, Núm. SUPPL. 1, pp. 28-36
2004
-
Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients
HIV Clinical Trials, Vol. 5, Núm. 1, pp. 33-39